Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRTHALACLIN: Sirolimus in Beta-thalassemia
NCT03877809Phase 2Completed
- Sponsor
- Rare Partners
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in beta thalassemia, sponsored by Rare Partners. Primary endpoint: Change from baseline of fetal hemoglobin level at 360 days. Started Jun 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT03877809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877809.